Skip to main content
Terug
RMYHY logo

Ramsay Health Care Limited

Datakwaliteit: 100%
RMYHY
OTC Healthcare Medical - Care Facilities
€ 6,98
€ 0,00 (0,00%)
Marktkapitalisatie: 6,42B
Ook genoteerd als RMSYF OTC
Dagbereik
€ 6,55 € 6,98
52-Weeksbereik
€ 4,31 € 7,18
Volume
8
50D / 200D Gem.
€ 6,52 / € 5,80
Vorige Slotkoers
€ 6,98

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 267,3 0,3
P/B 1,3 2,9
ROE % 0,5 3,7
Net Margin % 0,1 3,8
Rev Growth 5Y % 8,3 10,0
D/E 2,4 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,46
€ 0,46 – € 0,48
 21 B 1
FY2026 € 0,40
€ 0,40 – € 0,41
 20 B 1

Belangrijkste Punten

Revenue grew 8,27% annually over 5 years — modest growth
Earnings declined -97,30% over the past year
ROE of 0,48% is below average
Debt/Equity of 2,41 — high leverage
Generating 704,20M in free cash flow
P/E of 267,29 — premium valuation

Groei

Revenue Growth (5Y)
8,27%
Revenue (1Y)6,09%
Earnings (1Y)-97,30%
FCF Growth (3Y)10,32%

Kwaliteit

Return on Equity
0,48%
ROIC3,81%
Net Margin0,14%
Op. Margin4,93%

Veiligheid

Debt / Equity
2,41
Current Ratio0,90
Interest Coverage2,60

Waardering

P/E Ratio
267,29
P/B Ratio1,28
EV/EBITDA20,39
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 6,09% Revenue Growth (3Y) 8,63%
Earnings Growth (1Y) -97,30% Earnings Growth (3Y) -71,63%
Revenue Growth (5Y) 8,27% Earnings Growth (5Y) -51,92%
Profitability
Revenue (TTM) 17,67B Net Income (TTM) 24,00M
ROE 0,48% ROA 0,11%
Gross Margin 77,34% Operating Margin 4,93%
Net Margin 0,14% Free Cash Flow (TTM) 704,20M
ROIC 3,81% FCF Growth (3Y) 10,32%
Safety
Debt / Equity 2,41 Current Ratio 0,90
Interest Coverage 2,60 Dividend Yield 0,02%
Valuation
P/E Ratio 267,29 P/B Ratio 1,28
P/S Ratio 0,36 PEG Ratio -3,42
EV/EBITDA 20,39 Dividend Yield 0,02%
Market Cap 6,42B Enterprise Value 17,75B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 17,67B 16,66B 14,98B 13,18B 12,86B
Net Income 24,00M 888,70M 298,10M 274,00M 449,00M
EPS (Diluted) 0,03 0,97 0,31 0,29 0,48
Gross Profit 13,67B 2,01B 1,27B 900,60M 832,80M
Operating Income 870,50M 833,20M 1,64B 230,60M 1,59B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 22,48B 20,89B 21,13B 19,58B 19,39B
Total Liabilities 16,77B 15,37B 16,30B 15,06B 14,83B
Shareholders' Equity 5,02B 4,90B 4,15B 3,93B 4,03B
Total Debt 12,12B 10,94B 11,89B 10,70B 10,55B
Cash & Equivalents 784,40M 662,30M 656,10M 314,20M 2,96B
Current Assets 4,04B 3,87B 3,90B 3,29B 5,35B
Current Liabilities 4,47B 4,18B 3,81B 3,75B 3,72B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#393 of 618
26

Recente Activiteit

Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026